<DOC>
	<DOCNO>NCT00165698</DOCNO>
	<brief_summary>To determine effect safety menatetrenone treatment postmenopausal osteoporosis compare alfacalcidol .</brief_summary>
	<brief_title>Efficacy Safety Study Menatetrenone Treatment Postmenopausal Osteoporosis Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<mesh_term>Menatetrenone</mesh_term>
	<criteria>Inclusion criterion : Postmenopausal woman menopause duration 5 year age 4575 year old ( menopausal age ≥40 ) , hysterectomy operated natural menopause , age woman 6075 year old . Subject BMD ( L24 neck femur ) 2 Standard Deviation ( SD ) young female adult mean ( According standard center ) BMI 18 kg/m230 kg/m2 . The anatomic structure lumbar spine must available Dualenergy Xray Absorptiometry ( DEXA ) examination , patient serious scoliosis , bone trauma sequela orthopedics surgery , make BMD measurement difficult , exclude Subject give informed consent prior participation trial undertake comply protocol . Exclusion Criteria Subject condition consider effect osteoporosis , clear definite diabetes mellitus , rheumatoid arthritis , rheumatoid arthritis , hyperparathyroidism bone metabolic disease . Subjects receive treatment activetype vitamin D3 preparation , vitamin D preparation ( &gt; 1000IU per day） , calcitonin , corticosteroid hormone , androgen , estrogen , hormone , vitamin K preparation , 3 month prior inanition study ; Subjects receive treatment bisphosphonate preparation Sodium Fluoride 1 year prior inanition study ; Subjects receive treatment Selective Estrogen Receptor Modulator ( SERM ) 6 month prior inanition study Concurrent serious renal disease , hepatic disease , uncontrolled hypertension （≥150/100mmHg） , symptomatic ischemic heart disease , cerebral infarction arteriosclerosis obliterans . Cancer history within 5 year . Subjects take antacid contain aluminum preparation , warfarin thrombolytic agent . Subject know abnormality laboratory test , deem clinically significant investigator , include : Serum alkaline phosphatace ( ALP ) &gt; upper normal limit 10 % ( calculate accord range normal value center ) ; Glutamic Oxalacetic Transaminase ( AST ) / Glutamic Pyruvic Transaminase ( ALT ) &gt; upper normal limit 50％ ( calculate accord range normal value center ) ; Serum creatinine &gt; 1.5mg/dL ( 133μmol/L ) ; Bloodfasting sugar ≥ 7mmol/L ( 126mg/L ) Inability subject return schedule visit comply aspect protocol . Subject , opinion investigator , poor medical candidate pose risk therapy investigational drug .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Postmenopausal</keyword>
	<keyword>osteoporosis</keyword>
</DOC>